Similar articles for PMID: 33219159

Year	Number of Results
1951	1
1952	1
1978	1
1995	1
1997	1
1999	1
2000	1
2001	1
2002	1
2003	1
2004	2
2005	2
2006	3
2007	1
2008	1
2009	3
2010	5
2011	2
2012	5
2013	6
2014	6
2015	8
2016	9
2017	8
2018	8
2019	11
2020	15
2021	7
2022	2
2023	0

1

Management of Challenging Radioiodine Treatment Protocols: A Case Series and Review of the Literature.

Waller J, Lawhn-Heath CA, Edmonds C, Wendorf C, Holmes B, White M, Pampaloni MH, Liu C, Flavell RR. Waller J, et al. J Nucl Med Technol. 2021 Jun;49(2):180-185. doi: 10.2967/jnmt.120.255307. Epub 2020 Nov 20. J Nucl Med Technol. 2021. PMID: 33219159 Free article. Review.

2

Radioiodine Therapy in Patient with Differentiated Thyroid Cancer and End-Stage Renal Disease on Maintenance Hemodialysis: Case Report with Review of Literature.

Kumar M, Subramanian K, Tanwar KS, Prabhahar A, Divyaveer S, Sood A, Mittal BR, Sood A. Kumar M, et al. J Nucl Med Technol. 2022 Sep;50(3):228-232. doi: 10.2967/jnmt.121.261979. Epub 2021 Dec 6. J Nucl Med Technol. 2022. PMID: 34872920 Review.

3

Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update.

Ciarallo A, Rivera J. Ciarallo A, et al. AJR Am J Roentgenol. 2020 Aug;215(2):285-291. doi: 10.2214/AJR.19.22626. Epub 2020 Jun 17. AJR Am J Roentgenol. 2020. PMID: 32551904 Review.

4

Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.

Iravani A, Solomon B, Pattison DA, Jackson P, Ravi Kumar A, Kong G, Hofman MS, Akhurst T, Hicks RJ. Iravani A, et al. Thyroid. 2019 Nov;29(11):1634-1645. doi: 10.1089/thy.2019.0143. Thyroid. 2019. PMID: 31637953

5

Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review.

Blumhardt R, Wolin EA, Phillips WT, Salman UA, Walker RC, Stack BC Jr, Metter D. Blumhardt R, et al. Endocr Relat Cancer. 2014;21(6):R473-84. doi: 10.1530/ERC-14-0286. Epub 2014 Oct 2. Endocr Relat Cancer. 2014. PMID: 25277792 Review.

6

Radioactive iodine in differentiated thyroid cancer: a national database perspective.

Orosco RK, Hussain T, Noel JE, Chang DC, Dosiou C, Mittra E, Divi V, Orloff LA. Orosco RK, et al. Endocr Relat Cancer. 2019 Oct;26(10):795-802. doi: 10.1530/ERC-19-0292. Endocr Relat Cancer. 2019. PMID: 31443087 Free PMC article.

7

Clinical Management of End-Stage Renal Disease Patients on Dialysis Receiving Radioactive Iodine Treatment.

AlSadi R, Aziz LC, Bohan M, Dewji S, Bouhali O, Djekidel M. AlSadi R, et al. Clin Nucl Med. 2021 Dec 1;46(12):977-982. doi: 10.1097/RLU.0000000000003915. Clin Nucl Med. 2021. PMID: 34661559

8

Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.

Ain KB. Ain KB. Endocrine. 2015 Sep;50(1):61-6. doi: 10.1007/s12020-015-0668-9. Epub 2015 Jun 25. Endocrine. 2015. PMID: 26109472 Review.

9

Advanced differentiated thyroid cancer: when to stop radioiodine?

Giovanella L, van Nostrand D. Giovanella L, et al. Q J Nucl Med Mol Imaging. 2019 Sep;63(3):267-270. doi: 10.23736/S1824-4785.19.03191-1. Epub 2019 Jul 1. Q J Nucl Med Mol Imaging. 2019. PMID: 31271271 Review.

10

The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008.

Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. Sacks W, et al. Thyroid. 2010 Nov;20(11):1235-45. doi: 10.1089/thy.2009.0455. Thyroid. 2010. PMID: 21062195 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed